Does Medullary Sponge Kidney Cause Kidney Stones?
Yes, medullary sponge kidney (MSK) is a definite cause of kidney stone formation, with approximately 60-70% of MSK patients developing nephrolithiasis during their lifetime. 1
The Evidence Linking MSK to Stone Formation
The relationship between MSK and kidney stones is well-established through multiple lines of evidence:
Epidemiological Data
MSK is significantly more prevalent in stone formers compared to the general population. Research demonstrates that MSK occurs in 8.5-12% of patients with nephrolithiasis, compared to only 1-1.5% in patients without kidney stones 2, 3. This 8-12 fold increased prevalence represents a highly significant statistical association (p < 0.001) 2.
Among patients diagnosed with MSK, approximately 70% will have radiographic evidence of nephrolithiasis 4. More importantly, MSK is associated with a lifetime risk of renal stones in 60% of patients 5.
Pathophysiological Mechanism
MSK is a congenital malformation characterized by cystic dilatation of the papillary and medullary collecting ducts 1. This anatomical abnormality creates urinary stasis within the dilated tubules, promoting crystal precipitation and stone formation. The AUA guidelines specifically recognize that nephrocalcinosis (which occurs in MSK) implies an underlying anatomic condition predisposing to stone formation 1.
Metabolic Profile
The majority (84.6%) of MSK patients with stones have identifiable metabolic abnormalities 4. These include:
- Hypercalciuria (58% of patients) - the most common abnormality
- Low urine volume (35%)
- Hyperuricosuria (27%)
- Hypocitraturia (19%)
- Elevated urinary sodium (15%)
- Hyperoxaluria (12%)
Importantly, metabolic disorders were detected in only 60% of MSK patients with stones, compared to 93% of stone formers without MSK 2. This suggests that MSK itself is an independent risk factor for stone formation, beyond metabolic abnormalities alone.
Stone Composition and Recurrence
Stones in MSK patients show varied composition similar to the general stone-forming population, including calcium oxalate monohydrate, calcium oxalate dihydrate, calcium phosphate apatite, and uric acid 4. Among MSK patients with nephrolithiasis, 33% develop recurrent stone events 4, confirming this is not a one-time occurrence but an ongoing risk.
Clinical Implications
Recognition as High-Risk Condition
The AUA guidelines classify patients with nephrocalcinosis (which includes MSK) as requiring additional metabolic testing, recognizing them as high-risk stone formers 1. MSK patients frequently present with:
- Recurrent kidney stones
- Episodic painless hematuria
- Urinary tract infections
- Distal renal tubular acidosis (dRTA)
- Chronic pain syndromes 6, 7
Important Caveat
Not all MSK patients develop stones. Approximately 30% of MSK patients have no evidence of nephrolithiasis 4. Notably, in one study, no patient without initial evidence of nephrolithiasis developed a stone event during follow-up, while those with stones had a 33% recurrence rate 4. This suggests that stone formation in MSK may be determined by additional factors beyond the anatomical abnormality alone.
Management Approach
For MSK patients with stones, treatment should follow standard stone prevention protocols 1:
- Fluid intake to achieve ≥2.5 liters urine output daily (Grade B recommendation)
- Metabolic evaluation with 24-hour urine collection analyzing volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine
- Dietary modifications based on metabolic profile:
- Limit sodium to 2,300 mg/day
- Maintain dietary calcium at 1,000-1,200 mg/day (do not restrict)
- Limit oxalate-rich foods if hyperoxaluria present
- Pharmacological therapy as indicated:
- Potassium citrate for hypocitraturia or low urinary pH
- Thiazide diuretics for hypercalciuria
- Treatment of associated dRTA when present 8
The key distinction is that MSK patients require lifelong vigilance and prophylaxis given the anatomical predisposition that cannot be corrected, combined with the high recurrence rate once stones develop.